In the TriNetX health record network, adults with type 2 diabetes starting a GLP-1 drug were compared with starters of six other diabetes classes. Pancreatic cancer was 30% to 39% more common among starters of metformin, sulfonylureas, thiazolidinediones and DPP-4 inhibitors than among GLP-1 starters. Against insulin the paper reports a lower hazard for GLP-1 users but a higher absolute risk, 0.15% against 0.11%.
Why it is interesting: The direction of the pancreatic cancer signal depends on which diabetes drug the comparison is made against.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.